Epidermal Growth Factor Receptor Inhibitors

Cutaneous Side Effects and Their Management

S. Monjazeb, Janice Wilson

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy," which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. Adverse effects of such treatments are thought to be less severe, but can still be significant. Because EGFR is preferentially expressed in epithelial tissues, including the skin and hair follicle, cutaneous side effects of these agents are quite common. Not only can these toxicities severely affect patients' quality of life, but in some specific instances, they can be associated with increased response to therapy. It is of paramount importance that clinicians familiarize themselves with and understand the basic management of the range of cutaneous adverse effects caused by these drugs.

Original languageEnglish (US)
Pages (from-to)5-7
Number of pages3
JournalSkin therapy letter
Volume22
Issue number5
StatePublished - Sep 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Skin
Hair Follicle
Therapeutics
Epithelium
Quality of Life
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Epidermal Growth Factor Receptor Inhibitors : Cutaneous Side Effects and Their Management. / Monjazeb, S.; Wilson, Janice.

In: Skin therapy letter, Vol. 22, No. 5, 01.09.2017, p. 5-7.

Research output: Contribution to journalReview article

@article{d1b5506d4c024260b3bdc09e5349f547,
title = "Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management",
abstract = "Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as {"}targeted therapy,{"} which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. Adverse effects of such treatments are thought to be less severe, but can still be significant. Because EGFR is preferentially expressed in epithelial tissues, including the skin and hair follicle, cutaneous side effects of these agents are quite common. Not only can these toxicities severely affect patients' quality of life, but in some specific instances, they can be associated with increased response to therapy. It is of paramount importance that clinicians familiarize themselves with and understand the basic management of the range of cutaneous adverse effects caused by these drugs.",
author = "S. Monjazeb and Janice Wilson",
year = "2017",
month = "9",
day = "1",
language = "English (US)",
volume = "22",
pages = "5--7",
journal = "Skin therapy letter",
issn = "1201-5989",
publisher = "International Skin Therapy Newsletter, Inc.",
number = "5",

}

TY - JOUR

T1 - Epidermal Growth Factor Receptor Inhibitors

T2 - Cutaneous Side Effects and Their Management

AU - Monjazeb, S.

AU - Wilson, Janice

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy," which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. Adverse effects of such treatments are thought to be less severe, but can still be significant. Because EGFR is preferentially expressed in epithelial tissues, including the skin and hair follicle, cutaneous side effects of these agents are quite common. Not only can these toxicities severely affect patients' quality of life, but in some specific instances, they can be associated with increased response to therapy. It is of paramount importance that clinicians familiarize themselves with and understand the basic management of the range of cutaneous adverse effects caused by these drugs.

AB - Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy," which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. Adverse effects of such treatments are thought to be less severe, but can still be significant. Because EGFR is preferentially expressed in epithelial tissues, including the skin and hair follicle, cutaneous side effects of these agents are quite common. Not only can these toxicities severely affect patients' quality of life, but in some specific instances, they can be associated with increased response to therapy. It is of paramount importance that clinicians familiarize themselves with and understand the basic management of the range of cutaneous adverse effects caused by these drugs.

UR - http://www.scopus.com/inward/record.url?scp=85046575201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046575201&partnerID=8YFLogxK

M3 - Review article

VL - 22

SP - 5

EP - 7

JO - Skin therapy letter

JF - Skin therapy letter

SN - 1201-5989

IS - 5

ER -